La Jolla Pharmaceutical Co.
| Nasdaq: LJPC
La Jolla Pharmaceutical Co. is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of therapeutics for chronic organ failure and cancer. The company is focused on the clinical evaluation of GCS-100, a galectin antagonist, as a treatment for chronic organ disease and LJPC-501, an antagonist of the renin-angiotensin pathway, as a treatment for hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure. It also has several product candidates in the early development stage, including LJPC-101, a subcutaneous formulation of GCS-100, LJPC-201, an oral galectin-3 inhibitor and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. The company was founded in 1989 and is headquartered in San Diego, CA.